Inclusion in the new Trump pricing agreements that require discounts creates near-term pricing pressure on Alcon's outpatient drug revenues.
Alcon is named among nine companies newly agreeing to U.S. drug-pricing deals that "require the companies to offer discounts" on outpatient drugs. While the group pledged collective U.S. manufacturing investment, the immediate effect is downward price pressure on revenues for included drugmakers.
BridgeBio is named among companies required to offer outpatient drug discounts, implying reduced U.S. pricing and revenue pressure.
Eli Lilly is cited among firms previously folded into the administration's pricing deals, exposing it to the same pricing-down pressure.
Novo Nordisk is explicitly noted as expecting that higher prescription volumes will take time to offset revenue declines from lower U.S. drug prices.
Pfizer is listed among firms previously subject to the administration's pricing agreements, indicating vulnerability to reduced U.S. drug prices.
Teva is part of the new agreements and also agreed to donate APIs, actions that together imply pricing/operational impacts and short-term cost or revenue pressure.
Follow Alcon Inc. (ALC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ALC